BC Week In Review | Oct 6, 2017
Financial News

Roivant to invest $116.4M in Arbutus

Arbutus Biopharma Corp. (NASDAQ:ABUS) said Roivant Sciences GmbH (Basel, Switzerland) agreed to invest up to $116.4 million through the purchase of 1.2 million convertible preferred shares at a $7.13 conversion price, which represents a 15%...
BC Extra | Oct 2, 2017
Financial News

Roivant to invest $116.4M in Arbutus

Arbutus Biopharma Corp. (NASDAQ:ABUS) said Roivant Sciences GmbH (Basel, Switzerland) agreed to invest up to $116.4 million through the purchase of convertible preferred shares at a $7.13 conversion price, which represents a 15% premium to...
BC Week In Review | Oct 31, 2016
Company News

NeuroVive, Arbutus Biopharma deal

NeuroVive and Arbutus terminated a 2014 deal that granted OnCore Biopharma Inc. exclusive, worldwide rights to NVP018 to treat HBV infection. OnCore merged with Tekmira Pharmaceuticals Corp. in 2015 to form Arbutus. NeuroVive regained all...
BC Extra | Oct 21, 2016
Company News

Arbutus returns cyclophilin inhibitor to NeuroVive

NeuroVive Pharmaceutical AB (SSE:NVP; Pink:NEVPF) regained rights to NVP018 from Arbutus Biopharma Corp. (NASDAQ:ABUS) as the companies terminated a 2014 deal to develop the compound for HBV. The exclusive, worldwide rights to NVP018 were obtained...
BC Extra | Jul 21, 2015
Company News

Tekmira changing name to Arbutus with HBV focus

Tekmira Pharmaceuticals Corp. (NASDAQ:TKMR) said it will change its name to Arbutus Biopharma Corp., effective Aug. 3, and will focus on developing HBV therapies. It will form a separate business unit for non-HBV therapies, and...
BC Week In Review | Jun 22, 2015
Clinical News

TKM-Ebola-Guinea: Phase II data

Tekmira stopped enrollment in the open-label, African Phase II RAPIDE trial in patients with Ebola virus infection after a pre-defined futility analysis of the primary endpoint of mortality at day 14 showed that once-daily 0.3...
BioCentury | Jun 22, 2015
Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes Analyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 6/19 cls Aerie Pharmaceuticals Inc. (NASDAQ:AERI) Needham Serge Belanger Upgrade Buy (from hold) 54% $20.02 Belanger also set a $27...
BC Extra | Jun 20, 2015
Clinical News

Tekmira falls on Ebola data

Tekmira Pharmaceuticals Corp. (NASDAQ:TKMR) lost $1.74 (12%) to $13.28 on Friday on news its TKM-Ebola-Guinea was unlikely to show a therapeutic effect in the Phase II RAPIDE trial to treat Ebola virus infection. As a...
BC Innovations | Jun 18, 2015
Distillery Therapeutics

Therapeutics: Enolase 1 α (ENO1)

Cancer INDICATION: Colorectal cancer Cell culture, patient sample and mouse studies suggest conjugates of an ENO1-binding peptide with liposomes containing chemotherapeutics could help treat colorectal cancer (CRC). Phage display-based screening of 12-mer peptides for binding...
BC Week In Review | Apr 27, 2015
Clinical News

Patisiran: Extension study additional data

Additional data from 20 evaluable patients with TTR-mediated amyloidosis and familial amyloidotic polyneuropathy (FAP) in an open-label extension trial of an open-label, dose-escalation, international Phase II trial showed that 0.3 mg/kg IV patisiran every 3...
Items per page:
1 - 10 of 242
BC Week In Review | Oct 6, 2017
Financial News

Roivant to invest $116.4M in Arbutus

Arbutus Biopharma Corp. (NASDAQ:ABUS) said Roivant Sciences GmbH (Basel, Switzerland) agreed to invest up to $116.4 million through the purchase of 1.2 million convertible preferred shares at a $7.13 conversion price, which represents a 15%...
BC Extra | Oct 2, 2017
Financial News

Roivant to invest $116.4M in Arbutus

Arbutus Biopharma Corp. (NASDAQ:ABUS) said Roivant Sciences GmbH (Basel, Switzerland) agreed to invest up to $116.4 million through the purchase of convertible preferred shares at a $7.13 conversion price, which represents a 15% premium to...
BC Week In Review | Oct 31, 2016
Company News

NeuroVive, Arbutus Biopharma deal

NeuroVive and Arbutus terminated a 2014 deal that granted OnCore Biopharma Inc. exclusive, worldwide rights to NVP018 to treat HBV infection. OnCore merged with Tekmira Pharmaceuticals Corp. in 2015 to form Arbutus. NeuroVive regained all...
BC Extra | Oct 21, 2016
Company News

Arbutus returns cyclophilin inhibitor to NeuroVive

NeuroVive Pharmaceutical AB (SSE:NVP; Pink:NEVPF) regained rights to NVP018 from Arbutus Biopharma Corp. (NASDAQ:ABUS) as the companies terminated a 2014 deal to develop the compound for HBV. The exclusive, worldwide rights to NVP018 were obtained...
BC Extra | Jul 21, 2015
Company News

Tekmira changing name to Arbutus with HBV focus

Tekmira Pharmaceuticals Corp. (NASDAQ:TKMR) said it will change its name to Arbutus Biopharma Corp., effective Aug. 3, and will focus on developing HBV therapies. It will form a separate business unit for non-HBV therapies, and...
BC Week In Review | Jun 22, 2015
Clinical News

TKM-Ebola-Guinea: Phase II data

Tekmira stopped enrollment in the open-label, African Phase II RAPIDE trial in patients with Ebola virus infection after a pre-defined futility analysis of the primary endpoint of mortality at day 14 showed that once-daily 0.3...
BioCentury | Jun 22, 2015
Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes Analyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 6/19 cls Aerie Pharmaceuticals Inc. (NASDAQ:AERI) Needham Serge Belanger Upgrade Buy (from hold) 54% $20.02 Belanger also set a $27...
BC Extra | Jun 20, 2015
Clinical News

Tekmira falls on Ebola data

Tekmira Pharmaceuticals Corp. (NASDAQ:TKMR) lost $1.74 (12%) to $13.28 on Friday on news its TKM-Ebola-Guinea was unlikely to show a therapeutic effect in the Phase II RAPIDE trial to treat Ebola virus infection. As a...
BC Innovations | Jun 18, 2015
Distillery Therapeutics

Therapeutics: Enolase 1 α (ENO1)

Cancer INDICATION: Colorectal cancer Cell culture, patient sample and mouse studies suggest conjugates of an ENO1-binding peptide with liposomes containing chemotherapeutics could help treat colorectal cancer (CRC). Phage display-based screening of 12-mer peptides for binding...
BC Week In Review | Apr 27, 2015
Clinical News

Patisiran: Extension study additional data

Additional data from 20 evaluable patients with TTR-mediated amyloidosis and familial amyloidotic polyneuropathy (FAP) in an open-label extension trial of an open-label, dose-escalation, international Phase II trial showed that 0.3 mg/kg IV patisiran every 3...
Items per page:
1 - 10 of 242